In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
Reihe
Auflage
Softcover Reprint of the Original 1st 2018 ed.
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Zielgruppe
Illustrationen
13
1 s/w Abbildung, 13 farbige Abbildungen
XIII, 138 p. 14 illus., 13 illus. in color.
Maße
Höhe: 235 mm
Breite: 155 mm
Dicke: 9 mm
Gewicht
ISBN-13
978-3-030-09165-1 (9783030091651)
DOI
10.1007/978-3-319-75184-9
Schweitzer Klassifikation
Andrés J. M. Ferreri has a degree in Medicine from the Facultad de Medicina of the Universidad de Buenos Aires, Argentina (1985), and obtained the degree of Doctor in Medicine and Surgery in the Facoltà di Medicina e Chirurgia dell'Università degli Studi di Parma, Italy, in 1992. He is a Specialist in Clinical Oncology (Università degli Studi di Milan, Italy, 2005). He was a research fellow at the Divisione di Oncologia Sperimentale "E" and at the Divisione di Oncologia Médica "A" of the Istituto Nazionale dei Tumori of Milan (1989-1994) and vice-director of the Medical Oncology Unit of the San Raffaele Scientific Institute of Milan, Italy. Currently, Dr. Ferreri is Head of the Unit of Lymphoid Malignancies of the San Raffaele Scientific Institute of Milan, and is a Contract Professor of Oncology in the Vita e Salute University, Milan. He is fully devoted to the research on non-Hodgkin lymphomas and is an opinion leader in the field of extranodal lymphomas. Dr. Ferreri is Associate Editor of the ESO/START Project and of "Haematological Oncology" and Faculty of the European School of Oncology. Dr. Ferreri is a member of EHA, ESMO, ASH, and ASCO.
